Terms: = Endocrine gland cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Prognosis
241 results:
1. IFNα-induced BST2
Zheng C; Wang J; Zhou Y; Duan Y; Zheng R; Xie Y; Wei X; Wu J; Shen H; Ye M; Kong B; Liu Y; Xu P; Zhang Q; Liang T
Cell Rep; 2024 Apr; 43(4):114088. PubMed ID: 38602878
[TBL] [Abstract] [Full Text] [Related]
2. Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis.
Cigrovski Berkovic M; Coppola A; Sesa V; Mrzljak A; Lai Q
World J Gastroenterol; 2024 Feb; 30(7):759-769. PubMed ID: 38515954
[TBL] [Abstract] [Full Text] [Related]
3. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mtor signaling axis by binding to MYH9.
Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
[TBL] [Abstract] [Full Text] [Related]
4. Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts.
Arakawa Y; Jo U; Kumar S; Sun NY; Elloumi F; Thomas A; Roper N; Varghese DG; Takebe N; Zhang X; Ceribelli M; Holland DO; Beck E; Itkin Z; McKnight C; Wilson KM; Travers J; Klumpp-Thomas C; Thomas CJ; Hoang CD; Hernandez JM; Del Rivero J; Pommier Y
Cancer Res Commun; 2024 Mar; 4(3):834-848. PubMed ID: 38451783
[TBL] [Abstract] [Full Text] [Related]
5. TOP2A modulates signaling via the AKT/mtor pathway to promote ovarian cancer cell proliferation.
Zhang K; Zheng X; Sun Y; Feng X; Wu X; Liu W; Gao C; Yan Y; Tian W; Wang Y
Cancer Biol Ther; 2024 Dec; 25(1):2325126. PubMed ID: 38445610
[TBL] [Abstract] [Full Text] [Related]
6. Complexity of the Genetic Background of Oncogenesis in Ovarian cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract] [Full Text] [Related]
7. MK8722 initiates early-stage autophagy while inhibiting late-stage autophagy via FASN-dependent reprogramming of lipid metabolism.
Wang L; Zhu H; Shi Z; Chen B; Huang H; Lin G; Li J; Yu H; Xu S; Chen G; Ou R; Dai C
Theranostics; 2024; 14(1):75-95. PubMed ID: 38164137
[No Abstract] [Full Text] [Related]
8. Advances in understanding and management of high-grade pancreatic neuroendocrine neoplasm: a comprehensive review.
Regalla DKR; Deep O; Paluri RK
Chin Clin Oncol; 2023 Dec; 12(6):67. PubMed ID: 38073310
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic value of RRM1 and its effect on chemoresistance in pancreatic cancer.
Lin X; Tan Y; Pan L; Tian Z; Lin L; Su M; Ou G; Chen Y
Cancer Chemother Pharmacol; 2024 Mar; 93(3):237-251. PubMed ID: 38040978
[TBL] [Abstract] [Full Text] [Related]
10. A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment.
Alshareefy Y; Cummins S; Mazzoleni A; Sharma V; Guggilapu S; Leong AWY; Wireko AA
Medicine (Baltimore); 2023 Nov; 102(46):e36094. PubMed ID: 37986400
[TBL] [Abstract] [Full Text] [Related]
11. Characterization of the genomic alterations in poorly differentiated thyroid cancer.
Lee Y; Moon S; Seok JY; Lee JH; Nam S; Chung YS
Sci Rep; 2023 Nov; 13(1):19154. PubMed ID: 37932340
[TBL] [Abstract] [Full Text] [Related]
12. AKT and mtor expression in human pancreatic ductal adenocarcinoma. Relevance for tumor biology.
Handra-Luca A
Pathol Res Pract; 2023 Nov; 251():154878. PubMed ID: 37890271
[TBL] [Abstract] [Full Text] [Related]
13. SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic cancer.
Kim MJ; Kim HS; Kang HW; Lee DE; Hong WC; Kim JH; Kim M; Cheong JH; Kim HJ; Park JS
Cells; 2023 Oct; 12(20):. PubMed ID: 37887353
[TBL] [Abstract] [Full Text] [Related]
14. Circular RNAs: characteristics, functions, mechanisms, and potential applications in thyroid cancer.
Wu M; Yuan H; Zou W; Xu S; Liu S; Gao Q; Guo Q; Han Y; An X
Clin Transl Oncol; 2024 Apr; 26(4):808-824. PubMed ID: 37864677
[TBL] [Abstract] [Full Text] [Related]
15. Chloroxine inhibits pancreatic cancer progression through targeted antagonization of the PI3K/AKT/mtor signaling pathway.
Lin M; Xiao Y; Dai Y; Mao Y; Xu L; Zhang Q; Chen Z
Clin Transl Oncol; 2024 Apr; 26(4):951-965. PubMed ID: 37848695
[TBL] [Abstract] [Full Text] [Related]
16. Scoulerine promotes cytotoxicity and attenuates stemness in ovarian cancer by targeting PI3K/AKT/mtor axis.
Wang F; Zhang Y; Pang R; Shi S; Wang R
Acta Pharm; 2023 Sep; 73(3):475-488. PubMed ID: 37708956
[TBL] [Abstract] [Full Text] [Related]
17. VSIG2 promotes malignant progression of pancreatic ductal adenocarcinoma by enhancing LAmtor2-mediated mtor activation.
Xu J; Quan G; Huang W; Jiang J
Cell Commun Signal; 2023 Aug; 21(1):223. PubMed ID: 37626304
[TBL] [Abstract] [Full Text] [Related]
18. Piper longum Constituents Induce PANC-1 Human Pancreatic cancer Cell Death under Nutrition Starvation.
Fujihashi Y; Jo Kim M; Maneenet J; Awale S
Chem Biodivers; 2023 Sep; 20(9):e202300280. PubMed ID: 37612242
[TBL] [Abstract] [Full Text] [Related]
19. PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer.
Chen B; Lu X; Zhou Q; Chen Q; Zhu S; Li G; Liu H
PLoS One; 2023; 18(8):e0290031. PubMed ID: 37582104
[TBL] [Abstract] [Full Text] [Related]
20. Transcriptome data-based status of PI3K/AKT/mtor pathway indicates heterogeneity and immune modulation in patients with pancreatic ductal adenocarcinoma.
Xie P; Tan SY; Li HF; Tang HD; Zhou JH
J Gene Med; 2024 Jan; 26(1):e3570. PubMed ID: 37482968
[TBL] [Abstract] [Full Text] [Related]
[Next]